Quince Therapeutics Files 8-K on Shareholder Vote
Ticker: QNCX · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing-update
TL;DR
Quince Therapeutics had a shareholder vote on June 5th. Details to follow.
AI Summary
Quince Therapeutics, Inc. filed an 8-K on June 6, 2024, reporting on matters submitted to a vote of security holders on June 5, 2024. The company, formerly known as Cortexyme, Inc., is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This filing indicates that Quince Therapeutics held a shareholder vote, which could pertain to significant corporate actions or governance changes that may impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting a shareholder vote, with no immediate negative financial or operational news.
Key Numbers
- 001-38890 — SEC File Number (Identifies the company's filing history with the SEC.)
- 90-1024039 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Quince Therapeutics, Inc. (company) — Registrant
- June 5, 2024 (date) — Date of earliest event reported
- June 6, 2024 (date) — Date of report
- Cortexyme, Inc. (company) — Former company name
- 601 Gateway Boulevard, Suite 273, South San Francisco, California 94080 (address) — Principal executive offices
FAQ
What specific matters were submitted to a vote of Quince Therapeutics' security holders on June 5, 2024?
The filing states that matters were submitted to a vote of security holders on June 5, 2024, but does not specify the exact nature of these matters within the provided text.
When was Quince Therapeutics, Inc. formerly known as Cortexyme, Inc.?
The filing indicates the former company name was Cortexyme, Inc., with a date of name change listed as January 4, 2016.
What is the principal executive office address for Quince Therapeutics, Inc.?
The principal executive offices are located at 601 Gateway Boulevard, Suite 273, South San Francisco, California 94080.
What is the SIC code for Quince Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the fiscal year end for Quince Therapeutics, Inc.?
The fiscal year end for Quince Therapeutics, Inc. is December 31 (1231).
Filing Stats: 696 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-06-06 17:17:54
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share QNCX The Nasdaq Stock Mar
Filing Documents
- d844037d8k.htm (8-K) — 33KB
- 0001193125-24-156202.txt ( ) — 152KB
- qncx-20240605.xsd (EX-101.SCH) — 3KB
- qncx-20240605_lab.xml (EX-101.LAB) — 18KB
- qncx-20240605_pre.xml (EX-101.PRE) — 11KB
- d844037d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUINCE THERAPEUTICS, INC. Date: June 6, 2024 By: /s/ Dirk Thye Name: Dirk Thye Title: Chief Executive Officer